Alphamab subsidiary signs RMB10.24m development deal

Jiangsu Alphamab, a wholly-owned subsidiary of Alphamab Oncology, signed a Technology Development Agreement with Suzhou Alphamab for RMB10,240,000.

Suzhou Alphamab will provide technology development services for Jiangsu Alphamab's bispecific antibody-drug conjugate candidate, including production processes, analytical methods, and sample preparation for IND applications.

The three-year agreement runs from August 8, 2025, to July 31, 2028. Suzhou Alphamab is controlled by chairman Xu Ting, who is also a controlling shareholder of Alphamab Oncology.